Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2013; 3(9):687-691. doi:10.7150/thno.6381 This issue Cite

Research Paper

Tumor Spheroids as an In Vitro Model for Determining the Therapeutic Response to Proton Beam Radiotherapy and Thermally Sensitive Nanocarriers

Lakmini K. Senavirathna1, Ruchika Fernando1, Danny Maples1, Yuanshui Zheng2, Jerimy C. Polf 3, Ashish Ranjan1✉

1. Laboratory of Nanomedicine and Targeted Therapy, Department of Physiological Sciences, Center for Veterinary Health Sciences Oklahoma State University
2. Procure Proton Therapy Center, Oklahoma City
3. Department of Physics, College of Arts and Sciences, Oklahoma State University

✉ Corresponding author: Dr. Ashish Ranjan, Ph.D. 169 McElroy Hall, Physiological Sciences, Center for Veterinary Health Sciences, Stillwater, Oklahoma. Phone: 405-744-6292; Fax: 405-744-8263; Email: ashish.ranjanedu

Citation:
Senavirathna LK, Fernando R, Maples D, Zheng Y, Polf JC, Ranjan A. Tumor Spheroids as an In Vitro Model for Determining the Therapeutic Response to Proton Beam Radiotherapy and Thermally Sensitive Nanocarriers. Theranostics 2013; 3(9):687-691. doi:10.7150/thno.6381. https://www.thno.org/v03p0687.htm
Other styles

File import instruction

Abstract

Multicellular Tumor Spheroids (MCTS) strongly resemble tumor tissues, which makes them useful tools for radiation biology studies and screening of various chemotherapeutics. The goal of this pilot study was to use MCTS as an in vitro model to determine the response of cells to low temperature-sensitive liposomes (LTSLs) encapsulating doxorubicin (Dox) and proton beam radiotherapy (PBRT). Prior to treatment, MCTS were characterized for morphology and LTSLs were characterized for size, encapsulation efficiency, and ability to thermally release Dox (a model anticancer agent). Two groups of MCTS were treated with LTSL in combination with mild hyperthermia (40-42 °C) or PBRT alone in the presence of appropriate controls. Cytotoxic response was assessed after 48-72 h using an acid phosphatase assay. At 72 h, LTSL in combination with heat significantly reduced the viability of MCTS (15-30%) compared to the control (P < 0.05). A similar cytotoxic response was observed with PBRT treatment. The data suggest that like a monolayer cell culture, MCTS can be used to determine cytotoxic outcomes of thermal and proton therapy.

Keywords: Tumor spheroids, Liposomes, Proton beam radiotherapy, Drug delivery

Citation styles

APA
Senavirathna, L.K., Fernando, R., Maples, D., Zheng, Y., Polf, J.C., Ranjan, A. (2013). Tumor Spheroids as an In Vitro Model for Determining the Therapeutic Response to Proton Beam Radiotherapy and Thermally Sensitive Nanocarriers. Theranostics, 3(9), 687-691. https://doi.org/10.7150/thno.6381.

ACS
Senavirathna, L.K.; Fernando, R.; Maples, D.; Zheng, Y.; Polf, J.C.; Ranjan, A. Tumor Spheroids as an In Vitro Model for Determining the Therapeutic Response to Proton Beam Radiotherapy and Thermally Sensitive Nanocarriers. Theranostics 2013, 3 (9), 687-691. DOI: 10.7150/thno.6381.

NLM
Senavirathna LK, Fernando R, Maples D, Zheng Y, Polf JC, Ranjan A. Tumor Spheroids as an In Vitro Model for Determining the Therapeutic Response to Proton Beam Radiotherapy and Thermally Sensitive Nanocarriers. Theranostics 2013; 3(9):687-691. doi:10.7150/thno.6381. https://www.thno.org/v03p0687.htm

CSE
Senavirathna LK, Fernando R, Maples D, Zheng Y, Polf JC, Ranjan A. 2013. Tumor Spheroids as an In Vitro Model for Determining the Therapeutic Response to Proton Beam Radiotherapy and Thermally Sensitive Nanocarriers. Theranostics. 3(9):687-691.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use